EUVIMEDEUVIMED entdecken
Crossref

Investigating Occult GI Bleeds with Small bowel Capsule Endoscopy; what have we learnt?

B. A. Ogon, C. Walker, C. Goulding

Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S401

DOI: 10.1055/s-0044-1783697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von B. A. Ogon und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To assess the incidence of significant findings on SBCE; co-relate them with the haemoglobin levels, the use of antiplatelets/anticoagulant and the use of non-steroidal anti-inflammatory drugs in patients referred with OGIB.

Methods

Small bowel capsule data over three years from our centre was reviewed to identify patients referred with OGIB with no identifiable cause on OGD and colonoscopy. Haemoglobin at referral, the use of either anti platelets/anticoagulants as well as the use of NSAIDs were recorded. Results of SBCE of patients identified were analysed and lesions were classified according to the Saurin classification.

Results

We identified 83 patients; 56 males and 27 females with an average age of 62.5 years. The average haemoglobin at referral was 9.4g/dl. Of the 83 patients identified, 52 (63%) patients had a haemoglobin≤10g/dl. Of these 52, the most common finding on SBCE was angiodysplasia (Type 4 to Type 2 lesions) with 48% (25/52) of findings having a Saurin classification of P2. Of the 52 patients, 20 (38%) had no identifiable cause of OGIB on their SBCE. Of the 31 patients with a haemoglobin>10g/dl, the most common finding was angiodysplasia with 39% having a Saurin classification of p2 while 17 (55%) had no identifiable cause of OGIB. The odds ratio of finding a significant lesion (Saurin P2) with a Hb≤10g/dl versus a Hb>10g/dl is 1.5. A significant proportion of this cohort with OGIB (38/83; 46%) was noted to be on either an anti-platelet and or anti-coagulant. For this sub-group the most common finding on SBCE was angiodysplasia identified in 74% with 58%(22/38) having a Saurin classification of P2. Ten patients reported the use of NSAIDs frequently prior to capsule. Of the 10, 6 patients were noted to have gastric and or duodenal erosions or ulcerations on their SBCE with only two patients having a Saurin P2 lesion.

Conclusions

In this study, SBCE found a source of bleeding in 55% of those being investigated for OGIB thus providing a valuable tool for evaluation of this cohort. Overall, patients with a haemoglobin≤10g/dl and those on either an anti-coagulant or anti-platelet were more likely to have a significant finding (Saurin P2) on their capsule with angiodysplasia being the most common finding. Patients on NSAIDs were less likely to have a significant lesion beyond the duodenum, with gastric/duodenal erosion being the most common findin Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Ogon, B. A., Walker, C., & Goulding, C. (2024). Investigating Occult GI Bleeds with Small bowel Capsule Endoscopy; what have we learnt?. Endoscopy, 56(S 02 S 02), S401. https://doi.org/10.1055/s-0044-1783697

Vancouver

Ogon BA, Walker C, Goulding C. Investigating Occult GI Bleeds with Small bowel Capsule Endoscopy; what have we learnt?. Endoscopy. 2024;56(S 02 S 02):S401. doi:10.1055/s-0044-1783697

BibTeX
@article{Ogon2024,
  author = {Ogon, B. A. and Walker, C. and Goulding, C.},
  title = {Investigating Occult GI Bleeds with Small bowel Capsule Endoscopy; what have we learnt?},
  journal = {Endoscopy},
  year = {2024},
  volume = {56},
  number = {S 02 S 02},
  pages = {S401},
  doi = {10.1055/s-0044-1783697}
}
Kostenlos starten →